Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Electronic records final rule exemption of existing systems inappropriate, FDA says.

This article was originally published in The Tan Sheet

Executive Summary

ELECTRONIC RECORDS FINAL RULE's EXEMPTION OF EXISTING SYSTEMS INAPPROPRIATE, FDA states in a March 20 Federal Register notice announcing the agency's final rule on electronic records and signatures. The final rule represents "minimal standards," therefore, FDA says, a "general exemption for existing systems that do not meet these provisions would be inappropriate and is not in the public interest because such systems are likely to generate electronic records and electronic signatures that are unreliable, untrustworthy and not compatible with FDA's responsibility to promote and protect public health."

You may also be interested in...



E-Record Maintenance May Use “Time Capsule,” “Migration” Methods

The pharmaceutical industry may employ a "time capsule" or "migration" approach to maintain electronic records, FDA says in a draft guidance

E-Record Maintenance May Use “Time Capsule,” “Migration” Methods

The pharmaceutical industry may employ a "time capsule" or "migration" approach to maintain electronic records, FDA says in a draft guidance

E-Record Maintenance May Use “Time Capsule,” “Migration” Methods

The pharmaceutical industry may employ a "time capsule" or "migration" approach to maintain electronic records, FDA says in a draft guidance

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel